Jonathan W. Weinsaft, M.D.

Dr. Jonathan Weinsaft, an esteemed physician-scientist who focuses on clinical research and cardiovascular imaging, is the chief of the Greenberg Division of Cardiology at Weill Cornell Medicine and NewYork-Presbyterian/Weill Cornell Medical Center.

Dr. Jonathan Weinsaft directs the cardiac MRI program and participates in the cardiac CT angiography program at New York Presbyterian Hospital - Weill Cornell. In addition to their active clinical services, both programs are actively engaged several research studies aimed at improving diagnostic techniques as well as clinical risk stratification for patients with atherosclerotic heart disease and congestive heart failure.

Dr. Weinsaft is a member of the Division of Cardiology at NY Presbyterian Hospital - Weill Cornell Medical Center, where he is focused on the use of novel non-invasive imaging techniques such as cardiac MRI, cardiac CT, and nuclear cardiac imaging for the identification of coronary artery disease and related manifestations.

Dr. Weinsaft completed undergraduate and graduate studies at New York University and subsequently received his medical degree from the New York University School of Medicine. Dr. Weinsaft completed his Internal Medicine residency and Cardiology fellowship at the New York Presbyterian Hospital Weill Cornell Medical Center. He also completed a research fellowship in cardiovascular imaging at Duke University Medical Center, where he was subsequently on faculty prior to being recruited to NY Presbyterian Hospital & Weill Cornell to develop the cardiac MRI program. In addition to serving as the Michael J. Wolk Foundation Clinical Scholar at NYP - Cornell (2005), Dr. Weinsaft has received the American Heart Association's Laennec Society Young Clinician Award (2001), the American Society of Nuclear Cardiology Young Investigator Award (2003), and the Doris Duke Charitable Foundation Clinical Scientist Development Award (2006). Research interests include use of cardiac MRI and CT for identification of ischemic and infarcted myocardium as well as prognostic risk assessment.